We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · February 18, 2021

Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

The New England Journal of Medicine

 

Additional Info

Disclosure statements are available on the authors' profiles:

The New England Journal of Medicine
Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
N. Engl. J. Med 2021 Feb 13;[EPub Ahead of Print], R Motzer, B Alekseev, S-Y Rha, et al

Further Reading